Pricing Log in Create free account
Monday 9 November 2026 Export IKT’s income statement to Excel — free account

Inhibikase Therapeutics, Inc.

IKT

Healthcare Biotechnology

Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022.

EPS
0.00%
Free cash flow
−123.2%

Quarter to June 2026, against a year earlier

1.50 0.06 +4.17%
Market cap
$209.3M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
3.4×
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net bought
—
Trades
0 sells · 0 buys
Ownership
37.9%

Capital & Financial Ratios $m

Size
Market Cap 209
Revenue ttm 0
Net income ttm (61)
Free cash flow ttm (43)
Net debt Q (159)
Valuation
P/E n/m
Forward P/E n/m
Price / sales 1,005.2 (above 10: high)
Forward P/S Powerpack
Price / FCF n/m
Price / book 1.7
Financial health
Current ratio Q 15.8 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q 27.5
Growth
Revenue growth Q −100.0% (below 0%: shrinking)
Operating income growth Q −94.3% (below 0%: shrinking)
EPS, this year +11.0%
EPS, next year A −4.7% (below 0%: weak)
Revenue, next year A +3,216.7% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +6.4%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 395×, against a ten-year median of 1.2×; over the ten years it ranged from −224× in 2022 to 938× in 2026.
P/S against its own 10 years 89.76%
10-year low 10-year high
P/B against its own 10 years 61.52%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 13 98 179 159
Receivables — — — —
Inventory — — — —
Other 0 0 1 2
14 98 180 162
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — 3 —
3 4 8 10

Compound Annual Growth %

10y 5y 3y
Sales — (42.21%) (28.02%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 77.60% 101.81%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.09 Actual −0.11

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −0.09 −0.11 Miss by 0.02
Q4 FY25 −0.12 −0.09 Beat by 0.03
Q1 FY26 −0.10 −0.10 Met by 0.00
Q2 FY26 −0.09 −0.11 Miss by 0.02
Q3 FY26 −0.11 — Reports 13 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.11) — — —
’25 (0.15) (0.11) (0.13) (0.09) (0.49)
’24 (0.73) (0.66) (0.65) (0.17) (1.16)
’23 (0.96) (1.11) (0.86) (0.63) (3.16)
’22 (1.08) (1.08) (1.08) (1.02) (4.32)
’21 (1.56) (1.32) (1.08) (1.20) (4.86)
’20 (0.40) (0.31) (0.49) (0.90) (2.10)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 1 1 0 0 3
’20 0 0 0 0 1
’19 — — — 0 1
’18 — — — — 4
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (12) — — —
’25 (4) (6) (11) (8) (28)
’24 (4) (5) (5) (5) (19)
’23 (6) (5) (4) (3) (18)
’22 (4) (4) (6) (4) (17)
’21 (4) (4) (2) (4) (14)
’20 0 0 0 (1) (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (12) — — —
’25 (4) (6) (11) (8) (28)
’24 (4) (5) (5) (5) (19)
’23 (6) (5) (4) (3) (18)
’22 (4) (4) (6) (4) (18)
’21 (4) (4) (2) (4) (14)
’20 0 0 0 (1) (1)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 2 4 1 1 3 0 0 — — 0 (29.2%) 0 0 22 +984.2%
Gross margin, % — 0.00 100.00 100.00 100.00 100.00 100.00 100.00 — — 100.00 +100.0 pt
EBT — 0 (2) (6) (3) (15) (18) (19) (28) (48) (61) +80.1%
EBT margin, % — (21.16) (53.27) (509.75) (407.72) (476.88) (14,630.63) (7,304.76) 0.00 0.00 0.00 +21.2 pt
Net income — 0 (2) (6) (3) (15) (18) (19) (28) (48) (61) n/m
Per share, $
Per share, $ Revenue — 0.20 3.02 0.82 0.51 1.02 0.03 0.04 0.00 0.00 0.00 n/m
Earnings — (0.04) (1.61) (4.20) (2.10) (4.86) (4.32) (3.16) (1.16) (0.49) (0.43) +36.8%
Cash flow — (0.01) 0.54 (0.25) (0.82) (4.71) (4.11) (3.00) (0.81) (0.28) (0.24) +48.1%
Capex — 0.00 0.00 0.00 0.00 0.00 (0.06) 0.00 0.00 0.00 0.00 n/m
Free cash flow — (0.01) 0.54 (0.25) (0.82) (4.71) (4.17) (3.00) (0.81) (0.28) (0.24) +48.1%
Book value — (0.14) (0.58) (3.29) 7.15 12.66 4.98 1.82 4.00 1.76 0.88 n/m
Shares, m — 10 1 1 1 3 4 6 24 98 134 +32.5%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — 0.00 0.0
P/S — 105.66 105.66 105.66 81.92 8.63 111.13 30.78 — — 1,005.21 78.5
P/B — 0.00 0.00 0.00 5.85 0.70 0.65 0.73 — — 1.71 1.1
EV/Sales — 105.65 105.65 105.65 61.93 (4.51) (75.51) (20.10) — — 394.78 39.8
EV/FCF — (155.88) (155.88) (155.88) (38.30) 0.98 0.53 0.29 — — (2.41) (72.0)
Cash, $m
Cash, $m Operating cash flow — 0 1 0 (1) (14) (17) (18) (19) (28) (43) +96.2%
Capex — — — — — — 0 0 — 0 0 (62.0%)
Free cash flow — 0 1 0 (1) (14) (18) (18) (19) (28) (43) +96.2%
Balance, $m
Balance, $m Working capital — (2) (2) (4) 10 38 21 11 95 172 152 n/m
Net debt — 0 0 0 (14) (41) (23) (13) (98) (179) (159) n/m
Shareholders’ equity — (1) (1) (4) 10 38 21 11 95 173 153 n/m
Returns, %
Returns, % ROA — (27.85) (151.24) (396.78) (38.43) (51.65) (53.57) (96.49) (48.66) (34.49) (48.04) (6.6) pt
ROIC — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE — 39.31 194.01 217.27 (107.58) (61.35) (60.74) (118.88) (52.00) (36.05) (51.96) (75.4) pt
People
People Employees — — — 2 3 7 7 9 16 35 — +61.1%
Revenue/emp, $m — 0.00 0.00 0.56 0.23 0.44 0.02 0.03 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2023 · latest quarter Dec 2023 · fundamentals updated 26 Oct 2026

Inhibikase Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SLGL Sol-Gel Technologies Ltd. $206.3M — (loss-making) — (loss-making) −96.58% (below 0%: shrinking) n/m −8.76% (below 0%: shrinking) 100.00% (704.23%) Compare
RNAC Cartesian Therapeutics, Inc. $205.1M — (loss-making) — (loss-making) −92.91% (below 0%: shrinking) −7.84% (below 0%: shrinking) −6.15% (below 0%: shrinking) 100.00% 0.00% Compare
DRUG Bright Minds Biosciences Inc. $204.2M — (loss-making) — — n/m −124.63% (below 0%: shrinking) 0.00% 0.00% Compare
PLX Protalix BioTherapeutics, Inc. $202.2M 10.5× 10.6× +27.07% (above 0%: growing) +2,280.95% (above 0%: growing) −94.09% (below 0%: shrinking) 60.99% 23.48% Compare
PALI Palisade Bio, Inc. $202.2M 1.8× — (loss-making) +19,900.00% (above 0%: growing) n/m −318.44% (below 0%: shrinking) 100.00% (2,339.60%) Compare
ARTV Artiva Biotherapeutics, Inc. $201.9M — (loss-making) — (loss-making) — n/m +13.60% (above 0%: growing) 100.00% 0.00% Compare
IKT Inhibikase Therapeutics, Inc. $200.9M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −123.23% (below 0%: shrinking) 0.00% 0.00%
ELDN Eledon Pharmaceuticals, Inc. $199.9M — (loss-making) — — n/m −28.02% (below 0%: shrinking) 0.00% 0.00% Compare
IFRX InflaRx N.V. $199.7M — (loss-making) — (loss-making) −128.93% (below 0%: shrinking) n/m +59.76% (above 0%: growing) 14,029.95% 0.00% Compare
Median of peers $202.2M — — −92.91% — −18.39% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 7.10%
Entities affiliated with Soleus Capital 22.90%
Sands Capital Life Sciences Pulse Fund II, L.P. 19.40%
Fairmount Healthcare Fund II L.P. 18.50%
Perceptive Advisors LLC 11.10%
ADAR1 Capital Management, LLC 10.90%
SP IKT Holdings LLC 10.10%
Nantahala Capital Management, LLC 5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Inhibikase Therapeutics, Inc. (IKT) Latest News

20 Oct

Impact 4 · · GlobeNewswire

11 Aug

Impact 3 ·

23 Jul

Impact 4 ·

12 May

Impact 3 · · GlobeNewswire

7 Apr

Impact 4 · · GlobeNewswire

26 Mar

Impact 3 · · GlobeNewswire

20 Nov

Impact 4 · · GlobeNewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires
Impact 4 · · GlobeNewswireClinical Trials ArenaClinical Trials ArenaClinical Trials ArenaMotley FoolClinical Trials ArenaMotley FoolGuruFocus.com
Impact 3 ·

14 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswireGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com

19 Aug

Impact 3 · · GlobeNewswire

14 Aug

Impact 3 · · GlobeNewswire

30 Jun

Impact 3 · · Simply Wall St.

14 May

Impact 4 · · GlobeNewswire

14 Apr

Impact 3 · · GlobeNewswire

4 Apr

Impact 4 ·

27 Mar

Impact 4 · · GlobeNewswire

5 Mar

Impact 3 ·

24 Feb

Impact 3 ·

18 Feb

Impact 4 ·

21 Jan

Impact 4 · · Simply Wall St.

23 Oct

Impact 4 · · TipRanks

22 Oct

Impact 4 · · GuruFocus.com

21 Oct

Impact 4 · · GlobeNewswire

18 Oct

Impact 3 · · GuruFocus.com

11 Oct

Impact 4 · · TipRanks
Impact 4 · · GuruFocus.com

10 Oct

Impact 4 · · TipRanks

9 Oct

Impact 4 · · MT Newswires
stockrow.com/IKT · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com